Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Is PSA velocity useful?

Nature Reviews Urology volume 6, pages 305–306 (2009)Cite this article

When a patient presents for assessment of prostate cancer risk, do serial measurements of PSA provide more-useful information than determination of a single PSA concentration? The authors of a new systematic review contend that the answer to this question is 'no'. Stacy Loeb cautions against hasty abandonment of PSA kinetics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vickers, A. J., Savage, C., O'Brien, M. F. & Lilja, H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 27, 398–403 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Loeb, S., Roehl, K. A., Catalona, W. J. & Nadler, R. B. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J. Urol. 177, 899–902 (2007).

    Article  PubMed  Google Scholar 

  3. Loeb, S. et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur. Urol. 54, 1073–1080 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cook, N. R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115, 928–935 (2007).

    Article  PubMed  Google Scholar 

  5. Pencina, M. J., D'Agostino, R. B. Sr, D'Agostino, R. B. Jr & Vasan, R. S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157–172 (2008).

    Article  PubMed  Google Scholar 

  6. Carter, H. B. et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J. Natl Cancer Inst. 98, 1521–1527 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Perrin, P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur. Urol. 49, 418–419 (2006).

    Article  PubMed  Google Scholar 

  8. Sutcliffe, P. et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol. Assess. 13, iii, xi–xiii 1–219 (2009).

    Article  Google Scholar 

Download references

Author information

Author notes

  1. S. Loeb, Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street (Marburg 1), Baltimore, MD 21287, USA stacyloeb@gmail.com

Authors and Affiliations

  1. Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    Stacy Loeb

Authors
  1. Stacy Loeb
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loeb, S. Is PSA velocity useful?. Nat Rev Urol 6, 305–306 (2009). https://doi.org/10.1038/nrurol.2009.93

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2009.93

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing